Trial Profile

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV 8736 (Primary) ; ABBV-382 (Primary) ; ABBV-382 (Primary) ; Lutikizumab (Primary) ; Risankizumab (Primary) ; Risankizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms Target CD
Sponsors AbbVie

Most Recent Events

30 Jan 2026 Number of treatment arms are increased from 6 to 7 by the addition of Experimental: Monotherapy: ABBV-8736 - OUS Only arm.
30 Jan 2026 Planned number of patients changed from 500 to 540.
26 Nov 2024 Planned End Date changed from 4 Aug 2028 to 1 Aug 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com